Hostname: page-component-cd9895bd7-q99xh Total loading time: 0 Render date: 2024-12-25T15:52:52.509Z Has data issue: false hasContentIssue false
  • English
  • Français

Atypical antipsychotics and diabetes

Published online by Cambridge University Press:  13 June 2014

Suzanne Reeves  and
Robert Howard
Robert Howard
Affiliation:
Section of Old Age Psychiatry, De Crespigny Park, Institute of Psychiatry, London, SE5 8AF, England
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Reviews
Information
Irish Journal of Psychological Medicine , Volume 19 , Issue 2 , June 2002 , pp. 63 - 65
Copyright
Copyright © Cambridge University Press 2002

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Markowitz, JS, Brown, CS, Moore, TR. Atypical antipsychotics Part 1: pharmacology, pharmacokinetics, and efficacy. Ann Pharmacother 1999; 33: 73–85.CrossRefGoogle ScholarPubMed
2.Allison, DB, Casey, DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 2001; 62(suppl 7): 22–31.Google ScholarPubMed
3.Meyer, JM. Novel antipsychotics and severe hyperlipidaemia. J Clin Psychopharmacol 2001; 214: 369–74.CrossRefGoogle Scholar
4.Hiles, B. Hyperglycaemia and glycosuria following chlorpromazine therapy. JAMA 1956; 162: 1651.CrossRefGoogle Scholar
5.Schwarz, L, Munoz, R. Blood sugar levels in patients with chlorpromazine. Am J Psychiatry, 1968; 125: 253–4.CrossRefGoogle ScholarPubMed
6.Keskiner, A, el-Toumi, A, Bousquet, T. Psychotropic drugs, diabetes and chronic mental patients. Psychosomatics 1973; 14: 176–81.CrossRefGoogle ScholarPubMed
7.Liebzeit, KA, Markowitz, JS, Caley, CF. New onset diabetes and atypical antipsychotics. Eur Neuropsychopharmacol 2001; 11: 25–32.CrossRefGoogle ScholarPubMed
8.Mir, S, Taylor, D. Atypical antipsychotics and Hyperglycaemia. Int Clin Pharmacol 2001; 162: 63–74.Google Scholar
9.Muench, J, Carey, M. Diabetes mellitus associated with atypical antipsychotic medications: new case report and review of the literature. J Am Board Fam Pract 2001; 144: 278–82.Google Scholar
10.Hagg, S, Joelsson, L, Mjorndal, Tet al.Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with typical neuroleptic medications. J Clin Psychiatry 1998; 596: 294–99.CrossRefGoogle Scholar
11.Henderson, DC, Cagliero, E, Gray, Cet al.Clozapine, diabetes mellitus, weight gain and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry 2000; 1576: 975–81.CrossRefGoogle Scholar
12.Gale, EAM. Diabetes mellitus and other disorders of metabolism. In: Clinical Medicine 2nd ed. Kumar, PJ, Clark, ML (eds). London: Bailliere Tindall, 1990: 832–72.Google Scholar
13.Adams, PF, Marano, MA. Current estimates for the national interview survey, 1994. National Centre for Health Statistics, Vital Health Statistics 1995; 101: 93Google Scholar
14.Selva, KA, Scott, SM. Diabetic ketoacidosis associated with olanzapine in an adolescent patient. J Paediatr 2001; 1386: 936–7.CrossRefGoogle Scholar
15.Sobel, M, Jaggers, ED, Franz, MA. New-onset diabetes mellitus with the initiation of quetiapine treatment. J Clin Psychiatry 1999; 60: 556–7.CrossRefGoogle ScholarPubMed
16.Procyshyn, RM, Pande, S, Tse, G. New-onset diabetes mellitus associated with quetiapine. Can J Psychiatry 2000; 457: 668–9.Google Scholar
17.Croarkin, PE, Jacobs, KM, Bain, BK. Diabetic ketoacidosis associated with risperidone treatment. Psychosomatics 2000; 414: 369.CrossRefGoogle Scholar
18.Wirshing, DA, Spelberg, BJ, Erhart, SM, et al.Novel antipsychotics and new onset diabetes. Soc Biol Psychiatry 1998; 44: 778–83.CrossRefGoogle ScholarPubMed
19.Koval, MS, Rames, LJ, Christie, S. Diabetic ketoacidosis associated with clozapine treatment. Am J Psychiatry 1994; 151: 1520–52.Google ScholarPubMed
20.Colli, A, Cocciolo, M, Francobandiera, Cet al.Diabetic ketoacidosis associated with clozapine treatment. Diab Care 1999; 22: 176–177.CrossRefGoogle ScholarPubMed
21.Fertig, MK, Brooks, GV, Shelton, PSet al.Hyperglycaemia with olanzapine. J Clin Psychiatry 1998; 59: 687–9.CrossRefGoogle ScholarPubMed
22.Haffner, SM. Obesity and the metabolic syndrome: the San Antonio heart study. Br J Nutrition 2000; 83: 67–70.CrossRefGoogle ScholarPubMed
23.Hiltunen, L, Kivela, SL, Laara, Eet al.Progression of normal glucose tolerance to impaired glucose tolerance or diabetes in the elderly. Diab Res Clin Pract 1997; 352–3: 99–106.CrossRefGoogle Scholar
24.Melkersson, KI, Hulting, A-L, Brismar, KE. Elevated levels of insulin, leptin and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J Clin Psychiatry 2000; 61(10): 742–9.CrossRefGoogle ScholarPubMed
25.Yacizi, KM, Erbas, T, Yazici, AH. The effect of clozapine on glucose metabolism. Exp Clin Endocrin Diab 1998; 106: 475–7.CrossRefGoogle Scholar
26.Melkersson, KI, Hulting, A-L, Brismar, KE. Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses. J Clin Psychiatry 1999; 60(11): 783–91.CrossRefGoogle ScholarPubMed
27.Olefsky, J. M. Insulin resistance 1997. In: Diabetes Mellitus. 5th edn. Porte, D, Sherwin, RS (eds). Stamford, Conn: Appleton and Lange, 1997, 513–52.Google Scholar
28.Uvnas-Moberg, K, Alster, S, Hillegaart, V. Effects of selective serotonin and dopamine antagonists on plasma levels of glucose, insulin and glucagon in the rat. Neuroendocrin 1996; 63: 269–74.CrossRefGoogle Scholar
29.Yamada, J, Sugimoto, Y, Yoshikawa, IKet al.The involvement of the peripheral 5-HT2A receptor in peripherally administered serotonin-induced hyperglycaemia in rats. Life Sci 1995; 578: 819–25.CrossRefGoogle Scholar
30.Holden, RJ. Schizophrenia, suicide and the serotonin story. Med Hypotheses 1995; 44: 379–91.CrossRefGoogle ScholarPubMed
31.Kingsbury, SJ, Fayek, M, Trufasiu, Det al.The apparent effects of ziprasidone on plasma lipids and glucose. J Clin Psychiatry 2001; 62(5): 347–9.CrossRefGoogle ScholarPubMed
32.Brambilla, F, Guatalla, A, Guerrini, Aet al.Glucose-insulin metabolism in chronic schizophrenia. Dis Nerv System 1976; 37: 98–103.Google ScholarPubMed
33.Mukherjee, S, Decina, P, Bocola, Vet al.Diabetes mellitus in schizophrenic patients. Comp Psychiatry 1996; 37: 68–73.CrossRefGoogle ScholarPubMed
34.Dynes, JB. Diabetes in schizophrenia and diabetes in nonpsychotic medical patients. Dis Nerv System 1969; 30: 341–4.Google ScholarPubMed
35.Mukherjee, S, Schnur, DB, Reddy, R. Family history of type II diabetes in schizophrenic patients. Letter. Lancet 1989; 1: 495.CrossRefGoogle ScholarPubMed
36.Dixon, L, Weiden, P, Delahanty, Jet al.Prevalence and correlates of diabetes in national schizophrenic samples. Schizophrenia Bull 2001; 264: 903–12.Google Scholar
37.Lyon, ER. A review of the effects of nicotine on schizophrenia and antipsychotic medications. Psychiatr Serv 1999; 50: 1346–50.CrossRefGoogle ScholarPubMed
38.Brown, S, Birtwistle, J, Roe, Let al.The unhealthy lifestyle of people with schizophrenia. Psychol Med 1999; 29: 697–701.CrossRefGoogle ScholarPubMed
39.Holmberg, SK, Kane, C. Health care and self-practices of persons with schizophrenia. Psychiatr Serv 1999; 50: 827–9.CrossRefGoogle Scholar